475 related articles for article (PubMed ID: 11123289)
1. RANTES potentiates antigen-specific mucosal immune responses.
Lillard JW; Boyaka PN; Taub DD; McGhee JR
J Immunol; 2001 Jan; 166(1):162-9. PubMed ID: 11123289
[TBL] [Abstract][Full Text] [Related]
2. Lymphotactin acts as an innate mucosal adjuvant.
Lillard JW; Boyaka PN; Hedrick JA; Zlotnik A; McGhee JR
J Immunol; 1999 Feb; 162(4):1959-65. PubMed ID: 9973465
[TBL] [Abstract][Full Text] [Related]
3. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
[TBL] [Abstract][Full Text] [Related]
4. Viral macrophage-inflammatory protein-II: a viral chemokine that differentially affects adaptive mucosal immunity compared with its mammalian counterparts.
Singh UP; Singh S; Ravichandran P; Taub DD; Lillard JW
J Immunol; 2004 Nov; 173(9):5509-16. PubMed ID: 15494499
[TBL] [Abstract][Full Text] [Related]
5. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity.
Lillard JW; Singh UP; Boyaka PN; Singh S; Taub DD; McGhee JR
Blood; 2003 Feb; 101(3):807-14. PubMed ID: 12393512
[TBL] [Abstract][Full Text] [Related]
6. Expression of dual TCR on DO11.10 T cells allows for ovalbumin-induced oral tolerance to prevent T cell-mediated colitis directed against unrelated enteric bacterial antigens.
Zhou P; Borojevic R; Streutker C; Snider D; Liang H; Croitoru K
J Immunol; 2004 Feb; 172(3):1515-23. PubMed ID: 14734729
[TBL] [Abstract][Full Text] [Related]
7. Oral tolerance revisited: prior oral tolerization abrogates cholera toxin-induced mucosal IgA responses.
Kato H; Fujihashi K; Kato R; Yuki Y; McGhee JR
J Immunol; 2001 Mar; 166(5):3114-21. PubMed ID: 11207263
[TBL] [Abstract][Full Text] [Related]
8. Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue.
Hagiwara Y; McGhee JR; Fujihashi K; Kobayashi R; Yoshino N; Kataoka K; Etani Y; Kweon MN; Tamura S; Kurata T; Takeda Y; Kiyono H; Fujihashi K
J Immunol; 2003 Feb; 170(4):1754-62. PubMed ID: 12574339
[TBL] [Abstract][Full Text] [Related]
9. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice.
Kweon MN; Fujihashi K; VanCott JL; Higuchi K; Yamamoto M; McGhee JR; Kiyono H
J Immunol; 1998 Feb; 160(4):1687-93. PubMed ID: 9469425
[TBL] [Abstract][Full Text] [Related]
10. Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity.
Kataoka K; McGhee JR; Kobayashi R; Fujihashi K; Shizukuishi S; Fujihashi K
J Immunol; 2004 Mar; 172(6):3612-9. PubMed ID: 15004163
[TBL] [Abstract][Full Text] [Related]
11. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses.
Sakaue G; Hiroi T; Nakagawa Y; Someya K; Iwatani K; Sawa Y; Takahashi H; Honda M; Kunisawa J; Kiyono H
J Immunol; 2003 Jan; 170(1):495-502. PubMed ID: 12496436
[TBL] [Abstract][Full Text] [Related]
12. IgE enhances antibody and T cell responses in vivo via CD23+ B cells.
Getahun A; Hjelm F; Heyman B
J Immunol; 2005 Aug; 175(3):1473-82. PubMed ID: 16034084
[TBL] [Abstract][Full Text] [Related]
13. Mucosally induced systemic T cell unresponsiveness to ovalbumin requires CD40 ligand-CD40 interactions.
Kweon MN; Fujihashi K; Wakatsuki Y; Koga T; Yamamoto M; McGhee JR; Kiyono H
J Immunol; 1999 Feb; 162(4):1904-9. PubMed ID: 9973457
[TBL] [Abstract][Full Text] [Related]
14. Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity.
Boyaka PN; Marinaro M; Jackson RJ; van Ginkel FW; Cormet-Boyaka E; Kirk KL; Kensil CR; McGhee JR
J Immunol; 2001 Feb; 166(4):2283-90. PubMed ID: 11160283
[TBL] [Abstract][Full Text] [Related]
15. IL-12 is an effective adjuvant for induction of mucosal immunity.
Boyaka PN; Marinaro M; Jackson RJ; Menon S; Kiyono H; Jirillo E; McGhee JR
J Immunol; 1999 Jan; 162(1):122-8. PubMed ID: 9886377
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
17. Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses.
Kataoka K; Fujihashi K; Sekine S; Fukuiwa T; Kobayashi R; Suzuki H; Nagata H; Takatsu K; Shizukuishi S; McGhee JR; Fujihashi K
J Immunol; 2007 May; 178(10):6058-65. PubMed ID: 17475830
[TBL] [Abstract][Full Text] [Related]
18. Early events in peripheral regulatory T cell induction via the nasal mucosa.
Unger WW; Hauet-Broere F; Jansen W; van Berkel LA; Kraal G; Samsom JN
J Immunol; 2003 Nov; 171(9):4592-603. PubMed ID: 14568933
[TBL] [Abstract][Full Text] [Related]
19. Enteric infection acts as an adjuvant for the response to a model food antigen.
Shi HN; Liu HY; Nagler-Anderson C
J Immunol; 2000 Dec; 165(11):6174-82. PubMed ID: 11086051
[TBL] [Abstract][Full Text] [Related]
20. Nasally administered cholera toxin A-subunit acts as a mucosal adjuvant.
Campos EA; Namikoshi J; Maeba S; Yamamoto M; Fukumoto M; Yamamoto H
J Oral Sci; 2003 Mar; 45(1):25-31. PubMed ID: 12816361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
